<DOC>
	<DOC>NCT00347165</DOC>
	<brief_summary>The purpose of this study is to determine whether intravitreal injection of bevacizumab is effective in the treatment of neovascular age related macular degeneration</brief_summary>
	<brief_title>Intravitreal Bevacizumab for Age-Related Macular Degeneration</brief_title>
	<detailed_description>The neovascular age related macular degeneration(AMD) is a important cause of legal blindness in adults older than 50 years. Currently the treatment is photodynamic therapy that offer stabilization and limited visual improvement after 2 years of therapy. Bevacizumab has been reported effective used as intravenous injection for AMD. But serious side effects have been reported with the use of this drug in oncologic patients. The intravitreal use has been reported in limited case reports and safety and efficacy should be determined. The purpose of this study is efficacy and safety of 2.5 mg intravitreal of bevacizumab for AMD</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>age &gt;50 age related macular degeneration moderate to severe cataract glaucoma intraocular surgery diabetes mellitus non controlled hypertension coronary artery disease</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2006</verification_date>
	<keyword>macular degeneration</keyword>
	<keyword>angiogenesis</keyword>
	<keyword>antibodies</keyword>
</DOC>